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Abstract
This study assessed the prevalence and patterns of drug use among people living with HIV
(PLHIV) in Spain. We conducted an observational cross-sectional study including 1401
PLHIV. Data were collected through 33 sites across Spain using an online computer-assis-
ted self-administered interview. The survey measured use of illicit drugs and other sub-
stances, treatment adherence and health-related variables. To analyse patterns of drug use
we performed cluster analysis in two stages. The most frequently consumed substances
were: alcohol (86.7%), tobacco (55.0%), illicit drugs (49.5%), other substances (27.1%).
The most prevalent illicit drugs used were cannabis (73.8%), cocaine powder (53.9%), and
poppers (45.4%). Results found four clusters of PLHIV who used drugs. Two of them were
composed mainly of heterosexuals (HTX): Cluster 1 (n = 172) presented the lowest polydrug
use and they were mainly users of cannabis, and Cluster 2 (n = 84) grouped mostly men
who used mainly heroin and cocaine; which had the highest percentage of people who inject
drugs and presented the lowest level of treatment adherence (79.8±14.2; p < .0001). The
other two clusters were composed mainly of men who have sex with men (MSM), who were
mostly users of recreational drugs. Cluster 3 (n = 285) reported moderate consumption,
both regarding frequency and diversity of drugs used, while Cluster 4 (n = 153) was charac-
terized by the highest drug polyconsumption (7.4±2.2; p < .0001), and 4 grouped MSM who
injected recreational drugs, and who reported the highest frequency of use of drugs in a sex-
ual context (2.6±0.8; p < .0001) and rates of sexually transmitted infections (1.8±1.1; p <
.01). This is the largest multi-centre cross-sectional study assessing the current prevalence
and patterns of drug use among PLHIV in Spain. The highest prevalence of drug use was
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found among MSM, although HTX who used heroin and cocaine (Cluster 2) had the most
problems with adherence to HIV treatment and the worst health status.
Introduction
The human immunodeficiency virus (HIV) continues to be a major public health challenge in
Spain, with 145,000 people living with HIV (PLHIV) in 2016 [1]. Among the new HIV cases
that year, sexual transmission accounted for 79.6% of them, 53.1% of whom corresponded to
men who have sex with men (MSM) and 26.5% to heterosexuals (HTX), while only 3.6% were
attributed to people who inject drugs (PWID) [1]. Regarding prevalence, HTX and PWID
were still the largest subgroups of PLHIV, 32.5%, and 30.9% respectively, although their rela-
tive weight continued to decrease gradually in favour of MSM [2]. Both the effectiveness of the
highly active antiretroviral therapy (ART) and the high rate of access to treatment − nine out
of ten PLHIV in Spain − have led to a substantial mortality reduction over the last decades [3].
Despite the increased life expectancy for PLHIV, certain personal aspects may have an
important impact on their health care and health-related quality of life. One of these aspects is
substance use. A review on recreational drug use in PLHIV in Europe showed consumption
prevalence above 50% in most studies, especially in those focusing on MSM. Prevalence ranged
from 5.5 to 82.4% [4]. The ASTRA study found that 51% of 2,248 MSM PLHIV had used recre-
ational drugs in the previous three months in the UK [5]. In Spain, the prevalence of illicit
drug use in PLHIV remains unclear. The EMIS Survey, addressed to MSM only, found higher
consumption of illicit drugs in those PLHIV using many different recall periods [6]. A recent
study focusing on MSM with HIV in Madrid, Spain, found that 59% of them had used illicit
drugs during the previous year [7]. A similar prevalence over the same period has been
reported in the area of Catalonia, Spain [8]. With regard to individuals under treatment, a
study focusing on PLHIV attending one hospital found a prevalence of use of 44.2% in the last
12 months [9].
Studies to date have reported higher drug consumption rates in PLHIV compared with the
general population [10]. There is, however, considerable variability regarding the frequency of
use of the different drugs in the literature [4]. The EMIS study showed that poppers (56.2%),
cannabis (41.9%), cocaine (38.2%), sildenafil (32.9%), ecstasy (24.2%) and GHB/GBL (18.9%)
were the substances most frequently consumed over the past 12 months by MSM living with
HIV in Spain [11]. Some studies found that polydrug use, the use of various drugs over a pre-
defined period, was about 50% in some cases [9].
Studies have failed to identify clear patterns of drug consumption because the list of drugs
to be assessed varies significantly with time and across countries or social groups [9]. However,
the literature has highlighted two important patterns of drug use [12]. The first one, ‘chemsex’,
covers sexualized drug use and is practised mainly by MSM [12,13]. In the UK, the most com-
mon ‘chemsex’ drugs are crystal methamphetamine, GHB/GBL, mephedrone, and to a lesser
extent, ketamine [14,15]. In Spain, according to the U-SEX GESIDA-9416 study, cocaine was
the most frequent drug used in a sexual context, while crystal methamphetamine was the least
frequent [7]. Also, studies suggested that the practice of injecting recreational drugs at sex par-
ties − ‘slamming or slamsex’ − might be increasing in MSM [16]. The second pattern would
involve ‘party drugs’, such as cocaine, GHB, ketamine and amphetamines [12].
In addition to these patterns, there are still PLHIV using traditional intravenous drugs,
such as heroin or crack cocaine [6]. The literature on trends of drug use suggested that either
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fewer people are taking these drugs nowadays or users are switching to new drugs [17,18]. In
Spain, both the prevalence of use of heroin and its intravenous use decreased markedly from
the nineties to 2006 thanks to opioid substitution therapy, syringe exchange programmes and
replacement by other non-intravenous administration routes [19]. To our knowledge,
although the percentage of PLHIV using these drugs nowadays in Spain may be low, there are
no studies on the current prevalence and patterns of use of these substances.
Substance use may have a negative impact on HIV care and prevention. Some literature
showed a negative effect of illicit drug use on HIV disease [20]; on transmission risk behaviour
leading to the acquisition of sexually transmitted infections (STIs) [7,11,16], low adherence to
ART [21,22], and interactions with ART [23,24]. The first step to tackle this situation is to
understand the current use of these drugs. Thus, this study aimed to assess the prevalence of
drug use and to explore the patterns of consumption among PLHIV in Spain.
Materials and methods
Study design
This observational, cross-sectional study consisted of an electronic interview focusing on illicit
drug use in PLHIV. The study was performed in Spain, including data from 12 Spanish Auton-
omous Communities between November 2016 and May 2017. The interview was offered to
adults over 18 years old living with HIV under ART for at least one year. Participants with
severe psychiatric or cognitive disorders were considered not eligible.
We used a community-based participatory research paradigm, involving members of the
population under study in all research phases [25,26]. Also, a group of experts from several
social and health-care fields guided the research and participated in its different stages.
The Ethics Committee of the Hospital Clı́nico de Valencia approved the research protocol.
All procedures of the study followed the Helsinki Declaration principles, as well as the guide-
lines for good clinical practice.
Procedures
The study was coordinated by the Spanish AIDS society (SEISIDA), which contacted profes-
sionals from 36 institutions across the country. A total of 33 sites agreed to collaborate in the
study, 12 hospitals and 21 Non-Governmental Organizations (NGOs), which used conve-
nience sampling for participants’ inclusion. Of the total sample, 51.7% of the individuals were
recruited in NGOs.
The collaborating professionals included participants during their clinical visits or while
attending to various services. Additionally, a few NGOs recruited participants by e-mail. The
goals of the study were explained to potential participants, requesting their participation and
obtaining their signed informed consent. An online computer-assisted self-administered inter-
view (CASI) designed with Qualtrics was administered to participants with a tablet after pro-
viding appropriate instructions. Professionals were available to clarify any doubts or
difficulties during questionnaire completion. The average time needed to complete the ques-
tionnaire was 40 minutes.
We calculated an initial sample of 1,500 PLHIV distributed among the different participat-
ing sites across Spain. We distributed the sample in order to: (1) maintain the distribution of
the burden of HIV in the main Spanish regions, and (2) have an extensive geographical repre-
sentation. S1 Table shows the number and percentage of surveys collected by the different
Spanish regions and its HIV incidence in the last five years [1]. A total of 1,401 PLHIV agreed
to participate and finished the online survey (data are available from 10.6084/m9.figshare.
8059784). The final response rate was 93.4%, and it varied across sites ranging from 82 to
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100%. There were lower rates in hospitals compared with NGOs. Main reasons for refusing to
participate were lack of time, survey length, visual impairment or lack of skills to use tablets.
Participants were compensated with 15 euros.
Measures
We designed the survey according to the results of an earlier qualitative study and previous
evidence in the literature, following the methodological recommendations on the construction
of scales and wording of items [27,28]. The research team and the group of expert consultants
collaborated in the design process. The questionnaire was previously piloted and refined using
a sample of 61 PLHIV who used drugs. The survey contained the following variables:
Use of illicit drugs and other substances. The survey included a list of 18 illicit drugs
(Fig 1), their frequency of use and their route of administration. Besides, it included questions
asking participants about the frequency of alcohol use and smoking status. The survey also
incorporated items related to the consumption of other substances or medicines: erection
enhancers; methadone, morphine, and other opioids; anabolic steroids; sedatives or hypnotics,
antidepressants. The frequency of use for all substances except tobacco was rated on a 6-point
scale ranging from ‘sometimes in the last year’ to ‘daily’. Tobacco use was measured by the
amount of cigarettes smoked per day.
We also included items related to the drug consumption context: (a) use of drugs previous
to HIV diagnosis (yes/no); (b) main reasons for using drugs (8 reasons were listed and one
open question); and (c) frequency of use of drugs in a sexual context. Two items were rated on
a 4-point scale; these items were merged in the analyses due to the good correlation observed
(r = .59).
Treatment adherence and other health-related variables. We used the Questionnaire to
Evaluate the Adherence to HIV Therapy (CEAT-VIH) [29]. The 2.0 version of the scale is
comprised of 17 items rated on a 5-point scale. Negative items were reverse-coded. We calcu-
lated a composite score, with higher scores indicating higher treatment adherence. The scale
showed an adequate reliability in our study (Cronbach’s α = .78).
Moreover, the survey included the following questions related to participants’ health status:
years living with HIV; CD4 cell count; viral load; and STIs in the last year.
Finally, the questionnaire collected several socio-demographic characteristics: age; gender;
sexual orientation; level of education; employment status; financial resources; and city of
residence.
Data analysis
Frequencies, proportions, ranges, means, SDs and cross-tabulations were applied for descrip-
tive analysis. To analyse the diverse typologies of PLHIV, we performed a two-step cluster
analysis using demographics, health-related variables, types of drugs used, and route of con-
sumption. This analysis had been suggested as appropriate in clustering large data sets with
mixed attributes and allows the creation of models of clusters based on both categorical and
continuous variables [30,31]. Schwarz’s Bayesian criteria determined the number of clusters.
This method is known to be one of the most useful and objective selection criteria because it
avoids the arbitrariness in traditional clustering techniques [32,33]. Because the solution of the
cluster analysis could not be unique, the analysis was sometimes run changing the order of the
cases [32]. The research team discussed the final solution according to its conceptual meaning.
Once the groups were established, differences in variables under study were assessed using
Pearson’s chi square statistic for categorical variables and one-way analysis of variance
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(ANOVA) for continuous variables. Tukey’s HSD test was performed to compare differences
among groups.
Before starting the analysis, we examined the assumptions of multivariate analysis. We
found that the assumptions of independence and absence of multicollinearity of the variables
were fulfilled. However, some continuous variables did not meet the normality criteria of the
Fig 1. Prevalence and frequency of use of illicit drugs among PLHIV using drugs. N = 694.
https://doi.org/10.1371/journal.pone.0211252.g001
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distribution. Nevertheless, the literature suggests that two-step cluster analysis is robust about
the violations of distribution and independence criteria [32]. Furthermore, ANOVA is also
robust about the violations of normality and homoscedasticity criteria [34]. Nevertheless, we
checked the assessed differences with a non-parametric technique (Kruskal−Wallis).
The analyses were performed using the SPSS v.22 software.
Results
Participant characteristics
The study population consisted of 1,401 participants, with a mean age of 45.38 years
(SD = 10.19). Table 1 shows a summary of the socio-demographic characteristics of the











Prefer not to answer 19 (1.4)
Mode of transmission
Sexual intercourse 946 (67.5)
Sharing needles 272 (19.4)
Various practices concur 141 (10.1)
Other 42 (3)
Educational level
No studies 57 (4.1)
Primary 383 (27.4)
Secondary 484 (34.6)









� 1,000 € 539 (38.5)
1,000−1,500 € 405 (28.9)
1,500−2,000 € 104 (7.4)
> 2,000 € 168 (12)
Years since diagnosis, mean ±SD 14.1±9.6
Years taking ART, mean ±SD 11.6±8.4
Age, mean ±SD 45.3±10.1
Note: Data provided in percentages, except where specified. ART: antiretroviral therapy. SD: standard deviation.
https://doi.org/10.1371/journal.pone.0211252.t001
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participants. The survey did not collect gender identity in those participants who identified
themselves as transgender. Taking into account this limitation, we considered and labelled
self-defined male and female participants as cisgender throughout the manuscript.
Use of drugs and other substances
Alcohol was the substance most frequently consumed (86.7%). Ten per cent of the participants
consumed it daily. More than half of the individuals were smokers (55%). Most of them
smoked daily (84%), with an average of 13.1 cigarettes per day (SD = 8.5).
A total of 49.5% (n = 694) of participants stated to have used illicit drugs in the previous 12
months. The proportion of PLHIV who used illicit drugs was significantly higher in partici-
pants recruited from NGOs (54.9%) than from hospitals (43.8%), χ2 = 17.27, p< .0001. Over-
all, the vast majority of these participants had consumed illicit drugs before the HIV diagnosis
(84.7%).
The most prevalent illicit drugs were cannabis, cocaine and poppers. Cannabis was also the
most regularly consumed substance (Fig 1). Almost a quarter of PLHIV who used illicit drugs
consumed only cannabis (24.9%). The average number of different drugs used per participant
in the last 12 months was 3.3 (SD = 0.7; range: 1−14). Injected and rectal routes of administra-
tion accounted for 6.8% and 3.2% of the cases, respectively (Fig 2). Heroin, cocaine, and
mephedrone were the most frequent injected drugs; mephedrone and methamphetamine the
most intrarectally administered.
Fig 2. Frequencies of consumption routes used for the different types of illicit drugs. N = 694.
https://doi.org/10.1371/journal.pone.0211252.g002
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The use of some types of illicit drugs differed between the two biggest cities in Spain
(Madrid and Barcelona). Drugs that showed more differences between these cities were pop-
pers, ecstasy and mephedrone. In this sense, consumption of mephedrone and poppers were
higher in Madrid than in Barcelona (33.3% vs. 19.8%; χ2 = 7.78, p = .005 and, 68.5% vs. 56.9%;
X2 = 4.75, p = .029, respectively). Conversely, consumption of ecstasy and ketamine were
higher in Barcelona than in Madrid (37.1% vs. 27.2%; χ 2 = 3.73, p = .053 and, 22.8% vs. 13.0%;
χ 2 = 5.35, p = .021, respectively).
In addition to illicit drugs, 27.1% of the total sample (n = 379) consumed other substances.
PLHIV who used illicit drugs consumed them more prevalently than PLHIV who did not use
illicit drugs (37.0% vs. 17.3%, χ 2 = 69.40; p< .0001). The most frequent substance consumed
both among the total sample, and among PLHIV who used illicit drugs were erection enhanc-
ers (Fig 3).
Patterns of use of illicit drugs
The two-stage cluster analysis classified the participants into four groups. All the variables
included in the analysis contributed significantly to the formation of the groups. Table 2 sum-
marizes the consumers’ profiles in clusters according to socio-demographic characteristics and
use of drugs and other medicines or substances. Tables 3 and 4 display detailed information
and statistics.
Two clusters were composed mostly of HTX: cluster 1 (CL1) represented about 25% of
PLHIV who used illicit drugs and Cluster 2 (CL2) 12%. In these clusters, the mean age was
about 50 years, and participants had been living with HIV for more than 20 years. The analysis
classified most cisgender women in CL1. More than half of the participants in both clusters
had completed compulsory education only, and the majority had a monthly income of less
than 1,000 €. A large proportion of individuals in these clusters were retired or disabled. Shar-
ing needles was a frequent cause of HIV acquisition in both clusters, and was the main cause
in CL2. Patterns of drug use varied between these clusters. Individuals in CL1 consumed can-
nabis principally, followed by cocaine powder in 23% of cases. The analysis classified users of
Fig 3. Percentage of PLHIV who used other medicines or substances.
https://doi.org/10.1371/journal.pone.0211252.g003
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heroin in CL2, 32% of whom declared having used the injection route. Moreover, near to 60%
were also taking methadone and half of them antidepressants. Polydrug use in CL2 group was
higher than in CL1. The main reasons in both clusters to use drugs were ‘relaxing and avoiding
worries’, 47.1% and 63.1% in CL1 and CL2, respectively, and ‘removing negative feelings’,
35.4% and 44.1% in CL1 and CL2, respectively. According to their described profile, CL1 was
labelled ‘HTX mainly users of cannabis’ and CL2 ‘HTX users of heroin and cocaine’.
On the other hand, the other two clusters grouped MSM who had acquired HIV principally
through sexual intercourse. Cluster 3 (CL3) represented about 42% and Cluster 4 (CL4) 22%
of PLHIV using drugs. They were younger, had a higher level of education, higher socio-eco-
nomic status, and a more recent HIV diagnosis compared with HTX clusters (CL1 and CL2).
MSM in CL4 were the youngest participants and the ones with the most recent HIV diagnosis.
Both clusters differed in their pattern of drug use. CL3 presented a moderate consumption of
cannabis, poppers, and cocaine, while CL4 showed high rates of substance use for the most
types of drugs and the highest polydrug use. Furthermore, almost 10% of PLHIV in CL4 used
the injection route of consumption and 14.4% of them the anal route. Individuals in CL3 and
CL4 clusters reported a higher use of erection enhancers’ than in HTX clusters (CL1 and CL2).
The highest percentage was found among PLHIV in CL4 (92.2%). The main reasons to use
drugs in both clusters (CL3 and CL4) were ‘to enjoy the substances’ (54.7% and 81.1% for CL3
and CL4, respectively) and ‘sexual purposes’ (38.9% and 61.4%, respectively). According to
their described profile, CL3 was labelled ‘MSM with moderate drug use’, and CL4 ‘MSM high
polydrug users’.
Table 2. Cluster’s profile according to demographics, health-related data, use of drugs and other medicines.
Characteristics C1 (24.8%, n = 172) C2 (12.1%, n = 84) C3 (41.1%, n = 285) C4 (22.0%, n = 153)
Gender Mostly cis-men but the highest
percentage of cis-women among
clusters





Age ~ 50 years ~ 50 years ~ 40 years < 40 years
Sexual orientation Mainly HTX Mainly HTX Mainly MSM Mainly MSM
Educational level Low level The lowest level High level The highest level
Work situation Most retired or unemployed Most retired and the highest
percentage of unemployed
Most working Most working, the lowest percentage
of retired
Economic status Low The lowest Middle−high The highest
Mode of HIV
transmission
Mainly injection Mainly (the highest) injection Mainly sexual Mainly sexual
Time living with HIV More than 20 years More than 20 years Near to 10 years Less than 10 years
Type of drugs used Mainly users of cannabis and some of
them cocaine powder





The highest percentage of using most
types of drugs except heroin
Polyconsumption Low Medium Medium High
Routes of
consumption
Mainly smoked, some sniffed Mainly smoked and sniffed,
highest % of PWID
Mainly smoked, sniffed,
inhaled and around 1/3
oral
All routes. Some PWID. Anal route
Other medicines or
substances
Most sedatives and around 1/3
antidepressants. Some methadone and
erection enhancers
Mainly sedatives, methadone or
other opioids. Half of them
antidepressants
Mainly erection
enhancers and near to 1/
3 sedatives
Most erection enhancers (the highest
%), good few sedatives. The highest
% of anabolic users
Reasons for
consumption
Mainly relaxing or avoiding worries Mainly relaxing or avoiding
worries and negative feelings
Mainly to enjoy and
sexual purposes
Mainly to enjoy and sexual purposes
N = 694. HTX: heterosexual; MSM: men who have sex with other men.
https://doi.org/10.1371/journal.pone.0211252.t002
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PLHIV who did not use drugs
(n = 707)
Contrast statistica
Genderb χ2 = 186.97
Cis-men 61 78.6 96.1 100 71
Cis-women 38.4 19 0 0 28
Transgender 0.6 2.4 3.9 0 1
Sexual orientationb χ2 = 547.10
Heterosexual 86.6 85.7 6 0 48.4
Homosexual 2.9 3.6 87 94.8 44.1
Bisexual 6.4 6 4.6 3.3 3.8
Others 1.7 1.2 2.1 2 2.1
Prefer not to answer 2.3 3.6 0.4 0 1
Mode of transmission b χ2 = 458.65
Sexual intercourse 31.4 16.7 87 92.2 69.2
Sharing needles 57.6 75 0 0 15.6
Various practices concur 9.9 6 10.2 6.5 11.3
Other 1.2 2.4 2.8 1.3 4
Educational levelb χ2 = 273.76
No studies 8.7 14.5 1.1 0 3.8
Primary 50.6 61.4 11.6 8.5 28.1
Secondary 31.4 13.3 40.4 29.4 36.6
University degree 7 8.4 43.5 58.2 29.3
Other 2.3 2.4 3.5 3.9 2.1
Work situationb χ2 = 198.77
Working 23.8 13.1 69.1 69.3 46.7
Unemployed 22.1 34.5 16.1 20.9 15.8
Retired or occupational disability 41.3 41.7 8.4 3.9 26.7
Other 12.8 10.7 6.3 5.9 10.7
Monthly incomesb χ2 = 148.76
None 14.5 21.4 10.5 12.4 13.2
� 1,000 € 61 60.7 23.5 17.6 40.9
1,000−1,500 € 15.1 9.5 41.8 39.2 27.2
1,500−2,000 € 3.5 4.8 8.8 13.1 6.9
> 2,000 € 5.8 3.6 15.4 17.6 11.9
Inmunological status χ2 = 28.23
< 200 CD4 mm3 9.6 7.2 3.5 1.7 6.6
200−400 CD4 mm3 14.4 17.4 7.1 6 15.4
> 400 CD4 mm3 76 75.4 89.4 92.2 78
Undetectable viral load 93.3 87.8 94.4 97.4 93 χ2 = 9.02;
p = .061
Years since diagnosisb,1, mean ±SD 22.5±8.3 23.2±6.1 9.2±7.3 7.0±5.1 17.7±9.5 F = 114.36
Years taking ART2, mean ±SD 18.0±7.2 18.2±6.8 7.8±6.8 5.6±4.5 12.4±8.4 F = 82.09;
p = .000
ART adherence3, mean±SD 84.1±10.5 79.8±14.3 87.4±8.7 86.3±9.1 88.3±8.5 F = 20.83
Ageb,4, mean ±SD 50.9±6.4 49.5±5.5 41.1±9.4 36.8±8.3 47.1±10.3 F = 73.20
(Continued)
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Almost 40% of the individuals in CL3 and about 60% in CL4 reported using drugs in a sex-
ual context, while only around 3% in each HTX cluster used it. The frequency of use of drugs
in a sexual context also differed among clusters, and was higher in CL4 than in CL3 (Table 4).
Differences in ART adherence and other health-related variables according
to the profile of use of drugs
HTX ‘users of heroin and cocaine’ (CL2) showed the lowest score in ART adherence, followed
by HTX ‘mainly users of cannabis’ (CL1). MSM ‘high polydrug users’ (CL4) reported the high-
est percentage of STIs. MSM clusters of PLHIV who used illicit drugs (CL3 and CL4) reported
the highest lymphocytes CD4 mm3 count. The lowest percentage of patients with undetectable
viral load was found in CL2 (Table 3).
Discussion
The present research revealed the prevalence of illicit drug use as well as the particular patterns
of consumption among PLHIV in Spain. The most frequently consumed substances among
PLHIV in Spain, according to our results, were: alcohol (86.7%), tobacco (55.0%), illicit drugs
(49.5%) and other substances (27.1%). The prevalence of last-year alcohol consumption
among PLHIV was higher than that reported for the general Spanish population (77.6%),
although daily consumption resulted in similar results [35]. The prevalence of active smoking
was high compared with the general population (30.8%) [35]. Studies in other countries focus-
ing on PLHIV have reported similar results to those we found [36,37].
Almost half of the participants in our study had used illicit drugs in the last 12 months, with
cannabis, cocaine, and poppers being the most frequent ones. Cannabis and cocaine are also
the most consumed drugs in the general population [35,38] but the prevalence found in our
results was three times higher for cannabis and 13 times higher for cocaine than the respective
figures reported by the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) in the general population [10]. As for studies focusing on PLHIV, the prevalence
found in our study was slightly higher compared with the results by Garin et al. [9]. In addi-
tion, the prevalence of cocaine use among MSM who consume drugs in our sample was higher










PLHIV who did not use drugs
(n = 707)
Contrast statistica
STIs�5 (%, (m±SD) 10.5 (1.3±0.5) 13.1 (1.4±1.2) 30.9 (1.4±0.7) 60.8 (1.81±1.1) 16 (1.4±0.8) F = 3.71;
p< .01
Note: Data provided in percentages, except where specified. ART: antiretroviral therapy. STIs: sexually transmitted infections suffered in the last year (� percentage of
people in each cluster who had suffered any STI in the last year and mean of number of STIs suffered in the last year).
a All differences were significant at p < .0001 except when it is specified in the table.
b Variables included in two-stage cluster analysis.
1HSD Tukey results found differences between C1 and C2, C3, C4 and PLHIV who did not use illicit drugs (p < .0001); differences between C3 and C4 were marginally
different (p = .069)
2Differences were found between C1, C2, C3, C4 and PLHIV who did not use illicit drugs (p < .0001), and between C3 and C4 (p< .05)
3Differences were found between C1 and: C2 (p = .005),C3 (p = .002) and PLHIV who did not use illicit drugs (p< .0001), and between C2 and C3, C4 and PLHIV who
did not use illicit drugs (p < .0001)
4There were differences between all the groups (p < .0001) except between C1 and C2, and C2 and PLHIV who did not use illicit drugs
5 Significant differences were found between C4 and both C3 and PLHIV who did not use illicit drugs.
https://doi.org/10.1371/journal.pone.0211252.t003
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Table 4. Cluster’s profile according to the type and frequency of drugs used, routes of consumption and polyconsumption.
C1 (n = 172) C2 (n = 84) C3 (n = 285) C4 (n = 153) Contrast statistica
Drugs % (mean±SD)b,e
Cannabis 86.6 (4.4±1.8) 78.6 (4.1±2.0) 63.9 (3.1±2.0) 75.2 (3.1±2.0) χ2 = 30.32��� (F = 16.66���)
Cocaine (powder) 22.7 (1.6±0.9) 60.7 (2.5±1.6) 54.0 (1.6±0.9) 85.0 (1.9±1.1) χ2 = 128.49���(F = 10.19���)
Cocaine (base) 0 3.6 (2.7±1.6) 0 15.7 (2.1±0.8) χ2 = 75.45��� (F = .50, ns)
Heroin 0 69 (2.3±1.7) 0.4 (1.0±0.0) 0.7 (1.0±0.0) χ2 = 441.50��� (F = .55, ns)
Poppers 0 0 62.5 (1.8±1.2) 89.5 (2.2±1.3) χ2 = 366.59��� (F = 6.47�)
MDMA (crystal) 1.2 (1.0±0.0) 6 (1.8±1.7) 12.6 (1.0±0.2) 75.2 (1.4±0.7) χ2 = 314.70��� (F = 3.24�)
MDMA (pills) 0 16.7 (3.0±2.4) 11.9 (1.0±0.2) 72.5 (1.5±0.9) χ2 = 285.87��� (F = 16.99���)
Speed 4.1 (1.1±0.3) 21.4 (2.2±1.6) 8.1 (1.04±0.2) 67.3 (1.3±0.7) χ2 = 249.55��� (F = 6.96���)
Methamphetamine 0.6 (1.0±0.0) 2.4 (2.0±1.4) 3.9 (1.0±0.0) 43.8 (1.5±1.0) χ2 = 197.53��� (F = 1.17, ns)
GHB 0 2.4 (1.0±0.0) 19.3 (1.1±0.4) 77.1 (1.7±1.0) χ2 = 305.12��� (F = 11.45���)
Mephedrone 0 0 11.6 (1.0±0.3) 62.1 (1.6±0.9) χ2 = 260.60��� (F = 11.78��)
Ketamine 0.6 (1.0±0.0) 4.8 (1.0±0.0) 3.9 (1.0±0.0) 45.8 (1.4±0.8) χ2 = 202.55��� (F = .97, ns)
LSD 0 8.3 (1.3±0.7) 0.7(1.0±0.0) 9.8 (1.0±0.0) χ2 = 37.08��� (F = 1.24, ns)
Opium 0 7.1 (1.8±2.0) 0 2 (1.0±0.0) χ2 = 28.95��� (F = .46, ns)
Spice drugs 0 2.4 (1.5±0.7) 0.4 (1.0±0.0) 2 (1.0±0.0) χ2 = 6.77(ns) (F = 1.0, ns)
Mushrooms 0 3.6 (1.0±0.0) 0 15.7 (1.0±0.0) χ2 = 75.45��� (—)
Other hallucinogenic plants 0 8.3 (1.0±0.0) 0.4 (1.0±0) 2.6 (1.0±0.0) χ2 = 28.47��� (—)
2C-B nexus 0 1.2 (6.0±0) 0 1.3 (1.0±0.0) χ2 = 5.82(ns) (—)
Number of drugs used1 (mean±SD) 1.2±0.5 3.4±2.0 2.5±1.4 7.4±2.2 F = 461.06���
Use of drugs in sexual context% (mean±SD) c,2 3.5 (1.7±1.2) 3.6 (2.0±1.0) 38.9 (1.8±0.7) 61.4 (2.6±0.7) F = 16.67���
Routes of consumptiond,e %
Smoke 85.5 89.3 65.6 82.4 χ2 = 37.55���
Sniff 21.5 52.4 62.5 95.4 χ2 = 185.79���
Oral 5.2 31 35.1 98 χ2 = 304.21���
Injection 1.2 32.1 1.1 9.8 χ2 = 111.20���
Anal 0 0 0 14.4 χ2 = 80.33���
Inhaled 0.6 6 41.4 62.7 χ2 = 183.15���
Other medicines or substances used
Erection enhancers 19.4 18.8 62 92.2 χ2 = 89.86���
Methadone 19.4 59.4 0 0 χ2 = 113.99���
Morphine 3.2 9.4 0 1 χ2 = 11.84��
Other opioids 9.7 28.1 5.4 4.9 χ2 = 18.59���
Anabolic 0 0 2.2 18.6 χ2 = 24.87���
Sedatives 61.3 93.8 30.4 40.2 χ2 = 42.65���
Antidepressants 32.3 50 15.2 14.7 χ2 = 22.54���
a Measure of the importance of the categorical (χ2 = Pearson’s chi square) and continuous variables (one-way ANOVA) within each cluster. All χ2 differences were
significant at p< .0001 except when it is specified in the table. (—) F was not calculated in drugs for which only one cluster had the variance calculated.
b The frequency of consumption ranges from 1 to 6 (1: sometimes in the last 12 months; 2: once a month; 3: several times in a month; 4:once a week; 5: several times a
week; 6: daily).
c The frequency of the scale ranges from 1: sometimes, to 4: always.
d The score of each route of consumption was calculated summing the use of the route in each drug.
e Variables included in the two-step cluster analysis.
� p < .05
�� p < .01
��� p < .0001.
1HSD Tukey results found differences between all the clusters except between C2 and C3.
2 HSD Tukey results found differences between CL4 and CL1 and CL3.
https://doi.org/10.1371/journal.pone.0211252.t004
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other substances, such as poppers or ketamine. At an international level, several studies have
also highlighted the significant prevalence of illicit drug use in PLHIV across Europe. For
example, our results were similar to those found by Daskalopoulou et al. [5] in the United
Kingdom, although direct comparison is not possible since that study evaluated last-three-
months consumption. Grabovak et al. [39] found a moderately higher prevalence of drug use
in PLHIV in Austria but their analysis included sildenafil/tadalafil, categorized as ‘other sub-
stances’ in our study. In contrast, our prevalence results were higher compared with other
studies in France [40] or Scotland [37] although, again, differences in time frame make
comparisons.
Our study also found some differences in the pattern of drug use between the two largest
cities in Spain (Madrid and Barcelona). Similar results were found in a study conducted in
2016 that collected data from 486 MSM in Spain, who had practised ‘chemsex’ in the previous
12 months [41]. Findings of the EMIS study showed that the prevalence of use of the different
drugs varies substantially across cities, suggesting that drug use patterns appear to be culturally
and socially determined [42]. The association of the city of residence with drug use could be
influenced not only by psychological factors, but also by structural drivers such differences in
drug availability and differences in national, regional, or local norms and cultures concerning
drug use [42,43].
Regarding routes of consumption, we found that near to 7% of PLHIV who used illicit
drugs were using the injection route. They represented 3.4% of the total sample. This percent-
age is comparable to the HIV incidence results reported in Spain and the countries from the
European Union and European Economic Area [1,44].
Regarding patterns of drug use, our results found four clusters of PLHIV who used drugs.
Two of them were composed mostly of HTX and the other two principally of MSM, which
resulted in being the most prevalent group of PLHIV who used illicit drugs. MSM were the
youngest participants, had the most recent HIV diagnosis and the best socio-economic status.
These socio-demographic and epidemiologically different characteristics between MSM and
HTX living with HIV are concordant with those existing in the Spanish national HIV data
about HIV prevalence and incidence [1,2,45]. MSM and HTX clusters of PLHIV who used
illicit drugs found in the present study also differ in their reasons for using drugs. While HTX
aimed at avoiding worries or negative feelings, MSM pointed to issues such as enjoying their
use and sexual purposes.
Regarding clusters of HTX who used illicit drugs, the largest one was composed of people
who presented the lowest average of polydrug use and who were users of cannabis mainly fol-
lowed by cocaine powder. More than a half of them were former PWID and nearly one-fifth of
them were taking methadone in the period assessed by our study. Thus, they have given up or
replaced the use of heroin (or other injected drugs). In addition, a small group of HTX was
also found who were polydrug users and who showed the highest prevalence of heroin use and
current injection route. Although the majority of PLHIV in this cluster acquired HIV infection
through sharing needles, during the study period only near a third of them continued injecting
drugs. Taking the previous results conjointly, we can conclude that according to previous liter-
ature [19], both the use of heroin and its intravenous use have continued to decrease in Spain.
In our study, PLHIV in CL2 (mainly users of heroin and cocaine) represented around 6% of
the total sample and among them, 2% were PWID. Despite this decrease, it is essential to pay
attention to these groups of people because we found they presented the lowest levels of adher-
ence to treatment [20,21]. With this regard, PLHIV who were users of heroin and cocaine pre-
sented the poorest biological markers of HIV infection. However, not only the impact of their
use of drugs but also their socio-epidemiological profile could explain these results. The litera-
ture shows that PLHIV who use illicit drugs are more likely to experience problematic
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adherence and that they have increased age-matched morbidity compared to those who do not
use drugs [46,47]. A systematic review of interventions to improve adherence and virological
outcomes among PLHIV who used drugs concluded that directly administered antiretroviral
therapy (DAAT) obtained the most substantial evidence of efficacy but that it is labour-inten-
sive and costly to implement [46]. The arrival of long-acting treatments could be an opportu-
nity for DAAT in PLHIV who use illicit drugs. Nevertheless, DAAT should be complemented
with other interventions that have shown efficacy, such as cognitive behavioural therapy, moti-
vational interviewing and peer-driven interventions [46]. Besides interventions to promote
adherence, pharmacokinetic drug interactions must be adequately addressed in people who
use illicit drugs [47].
Among the MSM using drugs, there was a majority that reported moderate consumption,
both regarding frequency and diversity of drugs used. However, there was another pattern of
use in MSM, including younger patients with the highest frequency of illicit drug use and rele-
vant polydrug consumption. Some of them used drugs intra-rectally (around 14%) and intra-
venously (around 10%). PWID represented around 2% of the total MSM in our study. This
percentage was lower than that found by González-Baeza et al. [7] (around 4%) and similar to
the one found by Folch et al. [11] (1.4%). Prevalence of PWID in Folch et al. [11] was higher in
the largest towns. Baeza et al. [7] conducted their study exclusively in MSM with HIV living in
a large Spanish city (Madrid), where the use of recreational drugs and the practice of ‘slamsex’
seems to be higher than in smaller cities [11,18]. Regarding other countries, Pufall et al. [13]
found that 10% of the MSM interviewed in UK practised slamming in the previous year.
Although MSM clusters reported frequent use of drugs in a sexual context (32%) and high
rates of STIs in the previous 12 months, the percentages were the highest in MSM polydrug
users. These results are similar to those reported in the study of González-Baeza et al. [7].
Recent studies are highlighting the importance of the ‘chemsex’ phenomenon and its health
consequences among those who practise it [13,48,49]. Thus it will be necessary to monitor the
impact of drug use in the health and psycho-social sphere of MSM who use illicit drugs. It will
also be necessary to implement coordinated and multi-dimensional strategies that reduce
drug-related harm among them. Specific interventions could include: direct client service sup-
port to manage or reduce the use of drugs, health promotion activities, peer education support,
training healthcare providers and drug services about new recreational drugs and their role in
sexual intercourse, services to address specific psychological and psychiatric problems in MSM
who practice ‘chemsex’, advice about healthy leisure alternatives, harm-reduction services
such as needle exchange, among others. [41,50,51]. Moreover, several study findings suggest
that MSM who combine drugs with sex are more likely to engage in high-risk sexual practices
when compared with MSM who do not combine drugs with sex [43]. Thus, it will be necessary
to examine and increase the use of bio-medical risk reduction interventions such as STI test-
ing, post-exposure and pre-exposure prophylaxis to reduce the potential negative conse-
quences of ‘chemsex’ on public health [43].
Our study has several limitations. First, its cross-sectional nature does not allow causal rela-
tionships to be established. Second, we did not use a probabilistic sampling, although the large
sample size and extensive geographical data collection could mitigate this limitation. In this
sense, the socio-demographic characteristics of our participants were concordant with Spanish
epidemiological data for PLHIV [1]. Also, we aimed to provide a general overview of drug use,
including different PLHIV subgroups in Spain. This may make difficult direct comparison
with studies focusing on MSM only. However, the sample in our study involved a large pro-
portion of MSM, similar to that found in other studies [7], and specific analysis and results are
provided for this subgroup. Furthermore, we used a self-reported data collection method, and
this could underestimate the prevalence of PLHIV using drugs because some people would not
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desire to reveal this information to their health-care providers. However, we tried to overcome
this limitation through the anonymity of the survey and by balancing the data collection from
hospitals and NGOs. Furthermore, another limitation was that we measured the use of sub-
stances using single items. However, it allowed us to assess the use of several substances. More-
over, other studies had concluded the utility of single screening questions to identify substance
use [52]. Likewise, our survey asked about gender categories (men, women, transgender) con-
sidering them as mutually exclusive. However, many transgender people identify as men or
women, not as a third gender.
Conclusions
The present research is the largest multi-centre study assessing the current prevalence and pat-
terns of drug use among PLHIV in Spain. Our results showed a relatively high prevalence of
illicit drug use among the PLHIV in Spain. Prevalence of drug use in PLHIV was higher in
MSM than in HTX. MSM were mostly users of recreational and most recent drugs. Most of
them presented a moderate profile of drug consumption, although there was a specific sub-
group of MSM with high polyconsumption, which was associated with a higher risk of STIs.
HTX tend to use mainly cannabis, heroin or cocaine. Although the use of heroin and the injec-
tion route of consumption have decreased among them, PLHIV who still used heroin and
cocaine showed the most problems to adhere to HIV treatment and the worst health status.
Future studies should monitor the evolution of the patterns of drug use, and the longitudinal
impact of recreational drug use in their users’ health. Furthermore, it will be necessary to
design strategies that provide adequate responses to the diverse problems associated with each
pattern of drug use.
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Supervision: Ángeles Jaén, Carlos Iniesta, Santiago Cenoz, Marı́a José Galindo.
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